No Cover Image

Journal article 214 views 31 downloads

The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials

Leonardo Buttice Orcid Logo, Maryam Ghani, Janahan Suthakar, Sathyan Gnanalingham, Elliott Carande, Brett W. C. Kennedy, Alex Pitcher, James H. P. Gamble Orcid Logo, Mahmood Ahmad, Andrew Lewis, Peter Jüni, Oliver J. Rider, Jeffrey Stephens Orcid Logo, Jonathan J. H. Bray Orcid Logo

Diabetes, Obesity and Metabolism

Swansea University Author: Jeffrey Stephens Orcid Logo

  • 66055.pdf

    PDF | Version of Record

    © 2024 The Authors. This is an open access article under the terms of the Creative Commons Attribution License.

    Download (5.03MB)

Check full text

DOI (Published version): 10.1111/dom.15586

Abstract

AimsTo conduct a meta-analysis of randomized controlled trials (RCTs) to assess the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on inflammatory biomarkers.MethodsMedline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammato...

Full description

Published in: Diabetes, Obesity and Metabolism
ISSN: 1462-8902 1463-1326
Published: Wiley 2024
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa66055
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2024-04-15T07:53:39Z
last_indexed 2024-04-15T07:53:39Z
id cronfa66055
recordtype SURis
fullrecord <?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>66055</id><entry>2024-04-15</entry><title>The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials</title><swanseaauthors><author><sid>5219d126f97f8f884bdb622099bd41de</sid><ORCID>0000-0003-2228-086X</ORCID><firstname>Jeffrey</firstname><surname>Stephens</surname><name>Jeffrey Stephens</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2024-04-15</date><deptcode>MEDS</deptcode><abstract>AimsTo conduct a meta-analysis of randomized controlled trials (RCTs) to assess the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on inflammatory biomarkers.MethodsMedline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammatory biomarkers, adipokine profiles and insulin sensitivity.ResultsThirty-eight RCTs were included (14 967 participants, 63.3% male, mean age 62 ± 8.6 years) with a median (interquartile range) follow-up of 16 (12–24) weeks. Meta-analysis showed that SGLT2 inhibitors significantly improved adiponectin, interleukin-6, tumour necrosis factor receptor-1 (vs. placebo alone: standardized mean difference [SMD] 0.34 [95% confidence interval {CI} 0.23, 0.45], mean difference [MD] −0.85 pg/mL [95% CI −1.32, −0.38], SMD −0.13 [95% CI −0.20, −0.06], respectively), leptin and homeostatic model assessment of insulin resistance index (vs. control: SMD −0.20 [95% CI −0.33, −0.07], MD −0.83 [95% CI −1.32, −0.33], respectively). There were no significant changes in C-reactive protein (CRP), tumour necrosis factor-α, plasminogen activator inhibitor-1, fibroblast growth factor-21 or monocyte chemoattractant protein-1.ConclusionsOur analysis shows that SGLT2 inhibitors likely improve adipokine biomarkers and insulin sensitivity, but there is little evidence that SGLT2 inhibitors improve other inflammatory biomarkers including CRP.</abstract><type>Journal Article</type><journal>Diabetes, Obesity and Metabolism</journal><volume>0</volume><journalNumber/><paginationStart/><paginationEnd/><publisher>Wiley</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1462-8902</issnPrint><issnElectronic>1463-1326</issnElectronic><keywords>cardiovascular disease, dapagliflozin, empagliflozin, inflammation, mechanism of action, sodium-glucose co-transporter-2 inhibitors</keywords><publishedDay>11</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2024</publishedYear><publishedDate>2024-04-11</publishedDate><doi>10.1111/dom.15586</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>The authors received no funding.</funders><projectreference/><lastEdited>2024-05-22T12:27:41.7106696</lastEdited><Created>2024-04-15T08:49:54.0883585</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>Leonardo</firstname><surname>Buttice</surname><orcid>0000-0003-3527-2172</orcid><order>1</order></author><author><firstname>Maryam</firstname><surname>Ghani</surname><order>2</order></author><author><firstname>Janahan</firstname><surname>Suthakar</surname><order>3</order></author><author><firstname>Sathyan</firstname><surname>Gnanalingham</surname><order>4</order></author><author><firstname>Elliott</firstname><surname>Carande</surname><order>5</order></author><author><firstname>Brett W. C.</firstname><surname>Kennedy</surname><order>6</order></author><author><firstname>Alex</firstname><surname>Pitcher</surname><order>7</order></author><author><firstname>James H. P.</firstname><surname>Gamble</surname><orcid>0000-0001-9905-3337</orcid><order>8</order></author><author><firstname>Mahmood</firstname><surname>Ahmad</surname><order>9</order></author><author><firstname>Andrew</firstname><surname>Lewis</surname><order>10</order></author><author><firstname>Peter</firstname><surname>Jüni</surname><order>11</order></author><author><firstname>Oliver J.</firstname><surname>Rider</surname><order>12</order></author><author><firstname>Jeffrey</firstname><surname>Stephens</surname><orcid>0000-0003-2228-086X</orcid><order>13</order></author><author><firstname>Jonathan J. H.</firstname><surname>Bray</surname><orcid>0000-0003-1167-6295</orcid><order>14</order></author></authors><documents><document><filename>66055__30217__088940e17bb74c09a0418f4fb3724075.pdf</filename><originalFilename>66055.pdf</originalFilename><uploaded>2024-05-01T14:29:19.0494506</uploaded><type>Output</type><contentLength>5277094</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>© 2024 The Authors. This is an open access article under the terms of the Creative Commons Attribution License.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling v2 66055 2024-04-15 The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials 5219d126f97f8f884bdb622099bd41de 0000-0003-2228-086X Jeffrey Stephens Jeffrey Stephens true false 2024-04-15 MEDS AimsTo conduct a meta-analysis of randomized controlled trials (RCTs) to assess the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on inflammatory biomarkers.MethodsMedline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammatory biomarkers, adipokine profiles and insulin sensitivity.ResultsThirty-eight RCTs were included (14 967 participants, 63.3% male, mean age 62 ± 8.6 years) with a median (interquartile range) follow-up of 16 (12–24) weeks. Meta-analysis showed that SGLT2 inhibitors significantly improved adiponectin, interleukin-6, tumour necrosis factor receptor-1 (vs. placebo alone: standardized mean difference [SMD] 0.34 [95% confidence interval {CI} 0.23, 0.45], mean difference [MD] −0.85 pg/mL [95% CI −1.32, −0.38], SMD −0.13 [95% CI −0.20, −0.06], respectively), leptin and homeostatic model assessment of insulin resistance index (vs. control: SMD −0.20 [95% CI −0.33, −0.07], MD −0.83 [95% CI −1.32, −0.33], respectively). There were no significant changes in C-reactive protein (CRP), tumour necrosis factor-α, plasminogen activator inhibitor-1, fibroblast growth factor-21 or monocyte chemoattractant protein-1.ConclusionsOur analysis shows that SGLT2 inhibitors likely improve adipokine biomarkers and insulin sensitivity, but there is little evidence that SGLT2 inhibitors improve other inflammatory biomarkers including CRP. Journal Article Diabetes, Obesity and Metabolism 0 Wiley 1462-8902 1463-1326 cardiovascular disease, dapagliflozin, empagliflozin, inflammation, mechanism of action, sodium-glucose co-transporter-2 inhibitors 11 4 2024 2024-04-11 10.1111/dom.15586 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Another institution paid the OA fee The authors received no funding. 2024-05-22T12:27:41.7106696 2024-04-15T08:49:54.0883585 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science Leonardo Buttice 0000-0003-3527-2172 1 Maryam Ghani 2 Janahan Suthakar 3 Sathyan Gnanalingham 4 Elliott Carande 5 Brett W. C. Kennedy 6 Alex Pitcher 7 James H. P. Gamble 0000-0001-9905-3337 8 Mahmood Ahmad 9 Andrew Lewis 10 Peter Jüni 11 Oliver J. Rider 12 Jeffrey Stephens 0000-0003-2228-086X 13 Jonathan J. H. Bray 0000-0003-1167-6295 14 66055__30217__088940e17bb74c09a0418f4fb3724075.pdf 66055.pdf 2024-05-01T14:29:19.0494506 Output 5277094 application/pdf Version of Record true © 2024 The Authors. This is an open access article under the terms of the Creative Commons Attribution License. true eng http://creativecommons.org/licenses/by/4.0/
title The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
spellingShingle The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
Jeffrey Stephens
title_short The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
title_full The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
title_fullStr The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
title_full_unstemmed The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
title_sort The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
author_id_str_mv 5219d126f97f8f884bdb622099bd41de
author_id_fullname_str_mv 5219d126f97f8f884bdb622099bd41de_***_Jeffrey Stephens
author Jeffrey Stephens
author2 Leonardo Buttice
Maryam Ghani
Janahan Suthakar
Sathyan Gnanalingham
Elliott Carande
Brett W. C. Kennedy
Alex Pitcher
James H. P. Gamble
Mahmood Ahmad
Andrew Lewis
Peter Jüni
Oliver J. Rider
Jeffrey Stephens
Jonathan J. H. Bray
format Journal article
container_title Diabetes, Obesity and Metabolism
container_volume 0
publishDate 2024
institution Swansea University
issn 1462-8902
1463-1326
doi_str_mv 10.1111/dom.15586
publisher Wiley
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science
document_store_str 1
active_str 0
description AimsTo conduct a meta-analysis of randomized controlled trials (RCTs) to assess the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on inflammatory biomarkers.MethodsMedline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammatory biomarkers, adipokine profiles and insulin sensitivity.ResultsThirty-eight RCTs were included (14 967 participants, 63.3% male, mean age 62 ± 8.6 years) with a median (interquartile range) follow-up of 16 (12–24) weeks. Meta-analysis showed that SGLT2 inhibitors significantly improved adiponectin, interleukin-6, tumour necrosis factor receptor-1 (vs. placebo alone: standardized mean difference [SMD] 0.34 [95% confidence interval {CI} 0.23, 0.45], mean difference [MD] −0.85 pg/mL [95% CI −1.32, −0.38], SMD −0.13 [95% CI −0.20, −0.06], respectively), leptin and homeostatic model assessment of insulin resistance index (vs. control: SMD −0.20 [95% CI −0.33, −0.07], MD −0.83 [95% CI −1.32, −0.33], respectively). There were no significant changes in C-reactive protein (CRP), tumour necrosis factor-α, plasminogen activator inhibitor-1, fibroblast growth factor-21 or monocyte chemoattractant protein-1.ConclusionsOur analysis shows that SGLT2 inhibitors likely improve adipokine biomarkers and insulin sensitivity, but there is little evidence that SGLT2 inhibitors improve other inflammatory biomarkers including CRP.
published_date 2024-04-11T12:27:41Z
_version_ 1799752003013836800
score 11.017731

Similar Items